Conclusion

Under this section was not discussed the progress of Oncology-related methods of drug and radiation treatment of cancer, and yet they are obvious. It should be emphasized: immunotherapy is the youngest section of medical Oncology, so all the described approaches to the treatment of the terrible disease until they went out of experiment.
Cancer is an insidious and sophisticated enemy. In order to receive stem cell cancer should deceive protective of the host cell. If all the descendants of the progenitor of oncological diseases were completely similar, the cancer was not as protracted and difficult. But the fact of the matter is that the descendants of the initial tumor cells differ in their biological properties from the parent. The tumor is not always mono-and polyclonal. Genetic instability of tumor cells, their heterogeneity provide cancer extraordinary resilience. The frequency of mutations in bystrodeistviya tumors in 5-7 times higher than in neoplasticeskih. New tumor cells are often insensitive to those drugs that the tumor had "to get acquainted".
Getting used to anticancer drugs to tumors is significantly faster than in the organism as a whole. The emergence of resistant, resistant to this drug cells occurs quickly, and then cascading increases. In this case violated the cell membrane permeability, transition cytotoxic substances inside inhibit cancer cell proteins, the synthesis of which are in charge of the genes of a new group II (from "permeability"). Surgical removal of the tumor is the most effective, but it is reasonable addition methods of radiation and chemotherapy should not contradict immunological principles of development of malignant disease, and to take them into account and be combined with biotherapy enjoys. Moreover, it can be expected that certain approaches to immunotherapy will be used to surgical removal of the tumor. In any case, the treatment should be complex and fast.